FDA approves Xipere for treatment of macular edema associated with uveitis

The U.S. Food and Drug Administration (FDA) approved Xipere (triamcinolone acetonide injectable suspension; Bausch + Lomb) for suprachoroidal use for the treatment of macular edema associated with uveitis, according to a press release.

This is the first medicine approved in the US for delivery via suprachoroidal injection.

“The safety and efficacy data of Xipere was demonstrated in multiple clinical studies and its unique suprachoroidal administration approach provides exceptional access and high bioavailability to the posterior segment of the eye,” said Steven Yeh, MD, professor of ophthalmology and director of retinal disease and uveitis, Stanley M. Truhlsen Eye Institute, University of Nebraska Medical Center, and principal investigator for the Xipere Phase 3 (PEACHTREE) pivotal study, in a press release. “With the approval of XIPERE™, eye care professionals now have a new and innovative treatment option for their patients with macular edema associated with uveitis.”

Read the full press release here.